Published 1985 | Version v1
Report Restricted

Comparative impurity levels in iodine-123 produced by (p,2n) and (p,5n) reactions

  • 1. Benedict Nuclear Pharmaceuticals, Inc., Golden, CO

Description

Samples of two commercially available diagnostic drug products, one containing 123I produced by the 124Te(p,2n) → 123I reaction and the other containing 123I produced by the 127I(p,5n)123Xe → 123I reaction, were analyzed by gamma-ray spectroscopy. The impurities 124I, 125I, 126I, and 121Te were found in the (p,2n)-produced 123I, whereas only 125I and 121Te were detected in the (p,5n)-produced 123I. Quantitatively, the level of impurities measured in (p,2n)-produced 123I was substantially higher (4.0%) than that found in the (p,5n)-produced 123I (1.0%). Also, the gamma emissions from the impurities in the (p,2n)-produced 123I were primarily high-energy photons (i.e., above 159 KeV), which adversely affect both patient radiation dose and image quality

Files

Restricted

The record is publicly accessible, but files are restricted to users with access.

Additional details

Publishing Information

Imprint Title
Developing role of short-lived radionuclides in nuclear medical practice. DOE symposium series: 56
Journal Page Range
p. 471-474.
Report number
CONF-820523--

Conference

Title
International symposium on the developing role of short-lived radionuclides in nuclear medical practice.
Dates
3-5 May 1982.
Place
Washington, DC (USA).